658 related articles for article (PubMed ID: 30011897)
21. Alternative mechanism of action of the DNP Pt
Krasnovskaya O; Spector D; Erofeev A; Gorelkin P; Akasov R; Skvortsov D; Trigub A; Vlasova K; Semkina A; Zyk N; Beloglazkina E; Majouga A
Dalton Trans; 2021 Jun; 50(23):7922-7927. PubMed ID: 34037020
[TBL] [Abstract][Full Text] [Related]
22. Combining the platinum(ii) drug candidate kiteplatin with 1,10-phenanthroline analogues.
Pages BJ; Sakoff J; Gilbert J; Zhang Y; Kelly SM; Hoeschele JD; Aldrich-Wright JR
Dalton Trans; 2018 Feb; 47(7):2156-2163. PubMed ID: 29192713
[TBL] [Abstract][Full Text] [Related]
23. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Knox RJ; Friedlos F; Lydall DA; Roberts JJ
Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
[TBL] [Abstract][Full Text] [Related]
24. Role of carrier ligand in platinum resistance in L1210 cells.
Gibbons GR; Page JD; Mauldin SK; Husain I; Chaney SG
Cancer Res; 1990 Oct; 50(20):6497-501. PubMed ID: 2208108
[TBL] [Abstract][Full Text] [Related]
25. Synthesis, antiproliferative activity in cancer cells and DNA interaction studies of [Pt(cis-1,3-diaminocycloalkane)Cl
Hoeschele JD; Kasparkova J; Kostrhunova H; Novakova O; Pracharova J; Pineau P; Brabec V
J Biol Inorg Chem; 2020 Sep; 25(6):913-924. PubMed ID: 32851480
[TBL] [Abstract][Full Text] [Related]
26. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
Chen F; Qin X; Xu G; Gou S; Jin X
Biochem Pharmacol; 2017 Jul; 135():50-68. PubMed ID: 28288821
[TBL] [Abstract][Full Text] [Related]
27. Oxidative Stress Induced by Pt(IV) Pro-drugs Based on the Cisplatin Scaffold and Indole Carboxylic Acids in Axial Position.
Tolan D; Gandin V; Morrison L; El-Nahas A; Marzano C; Montagner D; Erxleben A
Sci Rep; 2016 Jul; 6():29367. PubMed ID: 27404565
[TBL] [Abstract][Full Text] [Related]
28. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines.
Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V
Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637
[TBL] [Abstract][Full Text] [Related]
29. Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance.
Huang X; Wang M; Wang C; Hu W; You Q; Yang Y; Yu C; Liao Z; Gou S; Wang H
Bioorg Chem; 2019 Nov; 92():103236. PubMed ID: 31494328
[TBL] [Abstract][Full Text] [Related]
30. Synthesis, characterization and cytotoxicity of new platinum(IV) axial carboxylate complexes: crystal structure of potential antitumor agent [PtIV(trans-1R,2R-diaminocyclohexane)trans(acetate)2Cl2].
Ali Khan SR; Huang S; Shamsuddin S; Inutsuka S; Whitmire KH; Siddik ZH; Khokhar AR
Bioorg Med Chem; 2000 Mar; 8(3):515-21. PubMed ID: 10732967
[TBL] [Abstract][Full Text] [Related]
31. Novel Kiteplatin Pyrophosphate Derivatives with Improved Efficacy.
Curci A; Gandin V; Marzano C; Hoeschele JD; Natile G; Margiotta N
Inorg Chem; 2017 Jul; 56(13):7482-7493. PubMed ID: 28636387
[TBL] [Abstract][Full Text] [Related]
32. Anti-cancer characteristics and ototoxicity of platinum(II) amine complexes with only one leaving ligand.
Monroe JD; Hruska HL; Ruggles HK; Williams KM; Smith ME
PLoS One; 2018; 13(3):e0192505. PubMed ID: 29513752
[TBL] [Abstract][Full Text] [Related]
33. Targeting ROS-AMPK pathway by multiaction Platinum(IV) prodrugs containing hypolipidemic drug bezafibrate.
Qiao X; Gao YY; Zheng LX; Ding XJ; Xu LW; Hu JJ; Gao WZ; Xu JY
Eur J Med Chem; 2021 Nov; 223():113730. PubMed ID: 34388483
[TBL] [Abstract][Full Text] [Related]
34. The role of carrier ligands of platinum(II) anticancer complexes in the protein recognition of Pt-DNA adducts.
He Y; Yuan J; Qiao Y; Wang D; Chen W; Liu X; Chen H; Guo Z
Chem Commun (Camb); 2015 Sep; 51(74):14064-7. PubMed ID: 26248639
[TBL] [Abstract][Full Text] [Related]
35. An Anticancer Pt
Kostrhunova H; Petruzzella E; Gibson D; Kasparkova J; Brabec V
Chemistry; 2019 Apr; 25(20):5235-5245. PubMed ID: 30740808
[TBL] [Abstract][Full Text] [Related]
36. Encapsulation of lipophilic kiteplatin Pt(iv) prodrugs in PLGA-PEG micelles.
Margiotta N; Savino S; Denora N; Marzano C; Laquintana V; Cutrignelli A; Hoeschele JD; Gandin V; Natile G
Dalton Trans; 2016 Aug; 45(33):13070-81. PubMed ID: 27094010
[TBL] [Abstract][Full Text] [Related]
37. Synthesis, characterization, and biological evaluation of new tetrazole-based platinum(II) and palladium(II) chlorido complexes--potent cisplatin analogues and their trans isomers.
Serebryanskaya TV; Yung T; Bogdanov AA; Shchebet A; Johnsen SA; Lyakhov AS; Ivashkevich LS; Ibrahimava ZA; Garbuzenco TS; Kolesnikova TS; Melnova NI; Gaponik PN; Ivashkevich OA
J Inorg Biochem; 2013 Mar; 120():44-53. PubMed ID: 23305964
[TBL] [Abstract][Full Text] [Related]
38. Mono- and di-bromo platinum(IV) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity.
Xu Z; Wang Z; Yiu SM; Zhu G
Dalton Trans; 2015 Dec; 44(46):19918-26. PubMed ID: 26514681
[TBL] [Abstract][Full Text] [Related]
39. Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells.
Gibbons GR; Kaufmann WK; Chaney SG
Carcinogenesis; 1991 Dec; 12(12):2253-7. PubMed ID: 1747924
[TBL] [Abstract][Full Text] [Related]
40. Potent Chlorambucil-Platinum(IV) Prodrugs.
Aputen AD; Elias MG; Gilbert J; Sakoff JA; Gordon CP; Scott KF; Aldrich-Wright JR
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
